CA2663057C - N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase - Google Patents
N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase Download PDFInfo
- Publication number
- CA2663057C CA2663057C CA2663057A CA2663057A CA2663057C CA 2663057 C CA2663057 C CA 2663057C CA 2663057 A CA2663057 A CA 2663057A CA 2663057 A CA2663057 A CA 2663057A CA 2663057 C CA2663057 C CA 2663057C
- Authority
- CA
- Canada
- Prior art keywords
- alkyl
- alkynyl
- alkenyl
- independently selected
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84570006P | 2006-09-19 | 2006-09-19 | |
| US60/845,700 | 2006-09-19 | ||
| PCT/US2007/078745 WO2008036642A2 (en) | 2006-09-19 | 2007-09-18 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2663057A1 CA2663057A1 (en) | 2008-03-27 |
| CA2663057C true CA2663057C (en) | 2015-12-08 |
Family
ID=38969441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2663057A Active CA2663057C (en) | 2006-09-19 | 2007-09-18 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080125470A1 (enExample) |
| EP (1) | EP2064207B1 (enExample) |
| JP (1) | JP5319532B2 (enExample) |
| CA (1) | CA2663057C (enExample) |
| ES (1) | ES2444574T3 (enExample) |
| WO (1) | WO2008036642A2 (enExample) |
Families Citing this family (162)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003201573B2 (en) * | 2002-01-22 | 2009-02-26 | Biomatera Inc. | Method of drying biodegradable polymers |
| US20080262031A1 (en) * | 2005-02-04 | 2008-10-23 | Ctg Pharma S.R.L. | 4-Aminoquinoline Derivatives as Antimalarials |
| PL2559690T3 (pl) | 2005-05-10 | 2016-09-30 | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania | |
| TWI382974B (zh) | 2005-12-20 | 2013-01-21 | 英塞特公司 | 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物 |
| WO2008036652A2 (en) * | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| JP5319532B2 (ja) * | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008058178A1 (en) * | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| ES2524266T3 (es) | 2008-07-08 | 2014-12-04 | Incyte Corporation | 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa |
| JP2016501203A (ja) | 2012-11-20 | 2016-01-18 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | インドールアミン２，３−ジオキシゲナーゼの阻害剤として有用な化合物 |
| WO2015031771A2 (en) * | 2013-08-30 | 2015-03-05 | Board Of Regents, The University Of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| EA201991770A1 (ru) | 2013-11-08 | 2019-12-30 | Инсайт Холдингс Корпорейшн | Способ синтеза ингибитора индоламин-2,3-диоксигеназы |
| HUE054183T2 (hu) | 2013-12-24 | 2021-08-30 | Bristol Myers Squibb Co | Triciklusos vegyület rákellenes szerekként |
| AU2015271709B2 (en) | 2014-06-06 | 2020-11-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof |
| EP3186371B1 (en) | 2014-08-29 | 2024-08-14 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| TWI711630B (zh) | 2014-11-21 | 2020-12-01 | 美商必治妥美雅史谷比公司 | 抗ｃｄ７３抗體及其用途 |
| AR103232A1 (es) | 2014-12-22 | 2017-04-26 | Bristol Myers Squibb Co | ANTAGONISTAS DE TGFbR |
| MY187045A (en) | 2014-12-23 | 2021-08-27 | Bristol Myers Squibb Co | Antibodies to tigit |
| US10983128B2 (en) | 2015-02-05 | 2021-04-20 | Bristol-Myers Squibb Company | CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy |
| PE20171789A1 (es) | 2015-03-02 | 2017-12-28 | Bristol Myers Squibb Co | Inhibidores del factor beta de crecimiento de transformacion (tgf-beta) |
| JP2018519245A (ja) | 2015-04-03 | 2018-07-19 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の治療のためのインドールアミン−２，３−ジオキシゲナーゼの阻害剤およびそれらの使用方法 |
| WO2016162505A1 (en) | 2015-04-08 | 2016-10-13 | F-Star Biotechnology Limited | Her2 binding agent therapies |
| BR112017020952A2 (pt) | 2015-04-13 | 2018-07-10 | Five Prime Therapeutics Inc | método de tratamento de câncer, composição e uso da composição |
| EP3294736B1 (en) | 2015-05-11 | 2020-07-22 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EP3307740B1 (en) | 2015-05-12 | 2019-12-18 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EA035412B1 (ru) | 2015-05-29 | 2020-06-10 | Бристол-Майерс Сквибб Компани | Антитела к ox40 и их применение |
| US10479838B2 (en) | 2015-06-29 | 2019-11-19 | Bristol-Myers Squibb Company | Antibodies to CD40 with enhanced agonist activity |
| KR20180034548A (ko) | 2015-07-28 | 2018-04-04 | 브리스톨-마이어스 스큅 컴퍼니 | Tgf 베타 수용체 길항제 |
| EP3341372A1 (en) | 2015-08-25 | 2018-07-04 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| JP6936221B2 (ja) | 2015-11-02 | 2021-09-15 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用 |
| CA3005855A1 (en) | 2015-11-19 | 2017-05-26 | Bristol-Myers Squibb Company | Antibodies against glucocorticoid-induced tumor necrosis factor receptor (gitr) and uses thereof |
| RU2745707C2 (ru) | 2015-11-23 | 2021-03-30 | Файв Прайм Терапьютикс, Инк. | Ингибиторы fgfr2 отдельно или в комбинации с иммуностимулирующими агентами в лечении рака |
| JP6856648B2 (ja) | 2015-12-15 | 2021-04-07 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｘｃｒ４受容体アンタゴニスト |
| WO2017140835A1 (en) | 2016-02-19 | 2017-08-24 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity |
| US11542486B2 (en) | 2016-03-02 | 2023-01-03 | Board Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| CA3016187A1 (en) | 2016-03-04 | 2017-09-08 | Bristol-Myers Squibb Company | Combination therapy with anti-cd73 antibodies |
| JP7038064B2 (ja) | 2016-04-18 | 2022-03-17 | セルデックス セラピューティクス インコーポレイテッド | ヒトｃｄ４０に結合するアゴニスト抗体およびその使用 |
| CN109414421A (zh) | 2016-05-04 | 2019-03-01 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| EP3452029A4 (en) | 2016-05-04 | 2019-10-30 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| WO2017192813A1 (en) | 2016-05-04 | 2017-11-09 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| JP2019516681A (ja) | 2016-05-04 | 2019-06-20 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| KR20190003685A (ko) | 2016-05-04 | 2019-01-09 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| SG11201900026TA (en) | 2016-07-14 | 2019-01-30 | Bristol Myers Squibb Co | Antibodies against tim3 and uses thereof |
| WO2018017633A1 (en) | 2016-07-21 | 2018-01-25 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
| CN109843322A (zh) | 2016-08-26 | 2019-06-04 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| UY37466A (es) | 2016-11-03 | 2018-01-31 | Phenex Discovery Verwaltungs Gmbh | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa |
| EP3842442B1 (en) | 2016-12-22 | 2023-11-01 | Precision Pharmaceuticals, Inc. | Compositions and methods for inhibiting arginase activity |
| US10961239B2 (en) | 2017-01-05 | 2021-03-30 | Bristol-Myers Squibb Company | TGF beta receptor antagonists |
| JP2020506895A (ja) | 2017-01-17 | 2020-03-05 | ボード オブ レジェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System | インドールアミン２，３−ジオキシゲナーゼおよび／またはトリプトファンジオキシゲナーゼの阻害剤として有用な化合物 |
| US11034661B2 (en) * | 2017-03-29 | 2021-06-15 | Merck Sharp & Dohme Corp. | Substituted N′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase IDO inhibitors |
| JP2020512357A (ja) | 2017-03-31 | 2020-04-23 | ファイブ プライム セラピューティクス， インコーポレイテッド | 抗ｇｉｔｒ抗体を使用した癌の併用療法 |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| FI3612030T3 (fi) | 2017-04-21 | 2026-03-20 | Pahr Therapeutics Inc | Ahr:n indoliestäjiä ja niiden käyttötapoja |
| AU2018258661A1 (en) | 2017-04-28 | 2019-10-17 | Five Prime Therapeutics, Inc. | Methods of treatment with CD80 extracellular domain polypeptides |
| US11066392B2 (en) | 2017-05-12 | 2021-07-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| KR101965348B1 (ko) * | 2017-06-26 | 2019-04-03 | 한국화학연구원 | N'-히드록시인다졸카르복시이미다미드 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용가능한 염, 및, 이를 유효성분으로 포함하는 항암용 조성물 |
| EP3645519A1 (en) * | 2017-06-28 | 2020-05-06 | GlaxoSmithKline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| BR112019026910A2 (pt) * | 2017-06-28 | 2020-06-30 | Glaxosmithkline Intellectual Property Development Limited | composto, composição farmacêutica, forma de dosagem unitária, método para tratar uma doença ou condição, e, uso de um composto ou sal. |
| EA202090119A1 (ru) | 2017-06-30 | 2020-04-21 | Бристол-Маерс Сквибб Компани | Аморфные и кристаллические формы ido-ингибиторов |
| ES2932354T3 (es) | 2017-07-28 | 2023-01-18 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticáncer |
| SG11202001310SA (en) | 2017-08-17 | 2020-03-30 | Ikena Oncology Inc | Ahr inhibitors and uses thereof |
| WO2019046498A1 (en) | 2017-08-31 | 2019-03-07 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| ES2904317T3 (es) | 2017-08-31 | 2022-04-04 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
| EP3676277A1 (en) | 2017-08-31 | 2020-07-08 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019043103A1 (en) * | 2017-09-01 | 2019-03-07 | Netherlands Translational Research Center B.V. | 3-HYDROXY-IMIDAZOLIDIN-4-ONE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE |
| WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| US11203592B2 (en) | 2017-10-09 | 2021-12-21 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2019074887A1 (en) | 2017-10-10 | 2019-04-18 | Bristol-Myers Squibb Company | CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| EP3697801B1 (en) | 2017-10-16 | 2024-11-20 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| CN111542544A (zh) | 2017-11-01 | 2020-08-14 | 百时美施贵宝公司 | 用于治疗癌症的免疫刺激性激动性抗体 |
| WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| WO2019115586A1 (en) | 2017-12-12 | 2019-06-20 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
| JP7284759B2 (ja) | 2017-12-27 | 2023-05-31 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｃｄ４０抗体およびその使用 |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| JP7358361B2 (ja) | 2018-01-12 | 2023-10-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| US11945834B2 (en) | 2018-03-08 | 2024-04-02 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| CA3093407A1 (en) | 2018-03-23 | 2019-09-26 | Bristol-Myers Squibb Company | Antibodies against mica and/or micb and uses thereof |
| US20210122757A1 (en) | 2018-03-29 | 2021-04-29 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
| JP2021521182A (ja) | 2018-04-12 | 2021-08-26 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｃｄ７３アンタゴニストとｐｄ−１／ｐｄ−ｌ１軸アンタゴニストの組み合わせ治療 |
| BR112020020772A2 (pt) | 2018-04-16 | 2021-02-02 | Board Of Regents, The University Of Texas System | enzimas quinureninase humana e usos das mesmas |
| AU2019255196A1 (en) | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| WO2019206800A1 (en) | 2018-04-24 | 2019-10-31 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
| US12037323B2 (en) | 2018-05-03 | 2024-07-16 | Bristol-Myers Squibb Company | Uracil derivatives as Mer-AXL inhibitors |
| US11866430B2 (en) | 2018-06-27 | 2024-01-09 | Bristol-Myers Squibb Company | Naphthyridinone compounds useful as T cell activators |
| RS64641B1 (sr) | 2018-06-27 | 2023-10-31 | Bristol Myers Squibb Co | Supstituisana jedinjenja naftiridinona korisna kao aktivatori t ćelija |
| TWI819024B (zh) | 2018-07-09 | 2023-10-21 | 美商戊瑞治療有限公司 | 結合至ｉｌｔ４的抗體 |
| WO2020014327A2 (en) | 2018-07-11 | 2020-01-16 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic ph |
| WO2020018670A1 (en) | 2018-07-17 | 2020-01-23 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| WO2020023356A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12059420B2 (en) | 2018-07-23 | 2024-08-13 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11130802B2 (en) | 2018-10-10 | 2021-09-28 | Tilos Therapeutics, Inc. | Anti-lap antibody variants |
| BR112021009111A2 (pt) | 2018-11-16 | 2021-08-24 | Bristol-Myers Squibb Company | Anticorpos anti-nkg2a e usos dos mesmos |
| WO2020231766A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| WO2020231713A1 (en) | 2019-05-13 | 2020-11-19 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| US20220306630A1 (en) | 2019-08-06 | 2022-09-29 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| MX2022003204A (es) | 2019-09-19 | 2022-04-18 | Bristol Myers Squibb Co | Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido. |
| KR20220103753A (ko) | 2019-11-19 | 2022-07-22 | 브리스톨-마이어스 스큅 컴퍼니 | 헬리오스 단백질의 억제제로서 유용한 화합물 |
| MX2022006308A (es) | 2019-11-26 | 2022-06-22 | Ikena Oncology Inc | Derivados de carbazol polimorfos y usos de los mismos. |
| WO2021108288A1 (en) | 2019-11-26 | 2021-06-03 | Bristol-Myers Squibb Company | Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
| ES3013568T3 (en) | 2019-12-23 | 2025-04-14 | Bristol Myers Squibb Co | Substituted heteroaryl compounds useful as t cell activators |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| WO2021133751A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
| BR112022012220A2 (pt) | 2019-12-23 | 2022-09-13 | Bristol Myers Squibb Co | Compostos de piperazina quinolinonil substituída úteis como ativadores de célula t |
| MX2022007130A (es) | 2019-12-23 | 2022-07-11 | Bristol Myers Squibb Co | Derivados de piperazina sustituidos utiles como activadores de celulas t. |
| CA3166898A1 (en) | 2020-01-06 | 2021-07-15 | Hifibio (Hk) Limited | Anti-tnfr2 antibody and uses thereof |
| WO2021139682A1 (en) | 2020-01-07 | 2021-07-15 | Hifibio (Hk) Limited | Anti-galectin-9 antibody and uses thereof |
| TW202140473A (zh) | 2020-01-15 | 2021-11-01 | 美商纜圖藥品公司 | Map4k1抑制劑 |
| EP4118118A1 (en) | 2020-03-09 | 2023-01-18 | Bristol-Myers Squibb Company | Antibodies to cd40 with enhanced agonist activity |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| US20230272056A1 (en) | 2020-04-09 | 2023-08-31 | Merck Sharp & Dohme Llc | Affinity matured anti-lap antibodies and uses thereof |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| US20230303695A1 (en) | 2020-08-10 | 2023-09-28 | Tengfei XIAO | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
| WO2022081718A1 (en) | 2020-10-14 | 2022-04-21 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| CA3202330A1 (en) | 2020-12-16 | 2022-06-23 | Anthony Casarez | Compounds useful as t cell activators |
| WO2022169921A1 (en) | 2021-02-04 | 2022-08-11 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
| CA3210553A1 (en) | 2021-02-12 | 2022-08-18 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| EP4305041A1 (en) | 2021-03-08 | 2024-01-17 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2022197641A1 (en) | 2021-03-15 | 2022-09-22 | Rapt Therapeutics, Inc. | 1h-pyrazolo[3,4-d]pyrimidin-6-yl-amine derivatives as hematopoietic progenitor kinase 1 (hpk1) modulators and/or inhibitors for the treatment of cancer and other diseases |
| EP4314068A1 (en) | 2021-04-02 | 2024-02-07 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| JP2024515545A (ja) | 2021-04-05 | 2024-04-10 | ブリストル－マイヤーズ スクイブ カンパニー | がん治療のためのピリジニル置換オキソイソインドリン化合物 |
| PT4320112T (pt) | 2021-04-06 | 2025-07-07 | Bristol Myers Squibb Co | Compostos de oxoisoindolina substituídos por piridinilo |
| MX2024000751A (es) | 2021-07-14 | 2024-03-25 | Blueprint Medicines Corp | Compuestos heterociclicos como inhibidores de map4k1. |
| CN117940406A (zh) | 2021-07-15 | 2024-04-26 | 缆图药品公司 | Map4k1抑制剂 |
| WO2023122772A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
| JP2025503312A (ja) | 2022-02-01 | 2025-01-30 | アルビナス・オペレーションズ・インコーポレイテッド | Ｄｇｋ標的化化合物およびその使用 |
| EP4568950A1 (en) | 2022-08-08 | 2025-06-18 | Bristol-Myers Squibb Company | Substituted tetrazolyl compounds useful as t cell activators |
| KR20250046310A (ko) | 2022-08-09 | 2025-04-02 | 브리스톨-마이어스 스큅 컴퍼니 | T 세포 활성화제로서 유용한 3급 아민 치환된 비시클릭 화합물 |
| JP2025526727A (ja) | 2022-08-11 | 2025-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式テトラヒドロチアゼピン誘導体 |
| TW202417001A (zh) | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫吖呯衍生物 |
| JP2025526681A (ja) | 2022-08-11 | 2025-08-15 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二環式テトラヒドロチアゼピン誘導体 |
| EP4568746B1 (en) | 2022-08-11 | 2026-04-29 | F. Hoffmann-La Roche AG | Bicyclic tetrahydrothiazepine derivatives |
| WO2024137865A1 (en) | 2022-12-22 | 2024-06-27 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| KR20250019700A (ko) | 2023-05-08 | 2025-02-10 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 페닐 옥사졸론 화합물 |
| WO2024233900A1 (en) | 2023-05-10 | 2024-11-14 | Blueprint Medicines Corporation | Gsk3a inhibitors and methods of use thereof |
| EP4719607A1 (en) | 2023-05-31 | 2026-04-08 | Bristol-Myers Squibb Company | Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins |
| AU2024285766A1 (en) | 2023-06-07 | 2026-01-08 | Bristol-Myers Squibb Company | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound |
| AU2024314878A1 (en) | 2023-06-23 | 2026-01-22 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent |
| WO2025030002A2 (en) | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| KR102834908B1 (ko) | 2023-09-02 | 2025-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | 치환된 페닐 옥소옥사졸릴 피페리딘 디온 화합물 |
| WO2025064197A1 (en) | 2023-09-02 | 2025-03-27 | Bristol-Myers Squibb Company | Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds |
| WO2025059245A1 (en) | 2023-09-13 | 2025-03-20 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compounds |
| US20250145590A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096487A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096490A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096488A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096505A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096489A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096494A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025226767A1 (en) | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
| WO2026035787A1 (en) | 2024-08-07 | 2026-02-12 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) macrocyles |
| WO2026080794A1 (en) | 2024-10-11 | 2026-04-16 | Bristol-Myers Squibb Company | Chemical compounds useful for degrading proteins |
| WO2026090348A1 (en) | 2024-10-24 | 2026-04-30 | Mirati Therapeutics, Inc. | The use of son of sevenless (sos) inhibitor compounds such as 7-substituted benzofurans to treat cancer |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3354174A (en) | 1964-02-19 | 1967-11-21 | Sterling Drug Inc | 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines |
| US3286855A (en) * | 1965-06-01 | 1966-11-22 | Standard Trailer Company | Crane extension and resulting crane assembly |
| US3553228A (en) * | 1967-09-26 | 1971-01-05 | Colgate Palmolive Co | 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles |
| DE2040628A1 (de) | 1970-08-17 | 1972-02-24 | Fahlberg List Veb | Neue herbizide Mittel |
| US3948928A (en) * | 1972-03-17 | 1976-04-06 | Dainippon Pharmaceutical Co., Ltd. | 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof |
| JPS5621033B2 (enExample) * | 1973-09-05 | 1981-05-16 | ||
| DD128918A5 (de) * | 1975-09-11 | 1977-12-21 | Philagro Sa | Phythohormonale und herbizide zusammensetzungen |
| FR2323683A1 (fr) | 1975-09-11 | 1977-04-08 | Philagro Sa | Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent |
| US4323681A (en) * | 1980-09-29 | 1982-04-06 | American Home Products Corporation | 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides |
| JPS58208275A (ja) | 1982-05-20 | 1983-12-03 | Lion Corp | ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤 |
| DE3462259D1 (de) * | 1983-07-22 | 1987-03-05 | Bayer Ag | Substituted furazans |
| JPS60193968A (ja) | 1984-03-13 | 1985-10-02 | Toyo Jozo Co Ltd | シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法 |
| JPS6259283A (ja) | 1985-09-10 | 1987-03-14 | Kaken Pharmaceut Co Ltd | セフアロスポリン化合物 |
| JP2696342B2 (ja) | 1988-06-27 | 1998-01-14 | 日本曹達株式会社 | アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤 |
| ES2051986T3 (es) | 1988-07-05 | 1994-07-01 | Akzo Nv | Compuestos con actividad broncodilatadora. |
| JPH04297449A (ja) | 1991-03-27 | 1992-10-21 | Hokko Chem Ind Co Ltd | Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤 |
| JPH05186458A (ja) | 1991-04-26 | 1993-07-27 | Japan Tobacco Inc | 新規なベンゾピラン誘導体 |
| FR2677019B1 (fr) * | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
| JP2709677B2 (ja) | 1992-06-19 | 1998-02-04 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| FR2720396B1 (fr) * | 1994-05-27 | 1996-06-28 | Adir | Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5731315A (en) * | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
| SK45898A3 (en) | 1995-10-17 | 1999-01-11 | Astra Pharma Prod | Pharmaceutically active quinazoline compounds |
| AU1730497A (en) | 1996-02-17 | 1997-09-02 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
| US5955495A (en) | 1996-05-03 | 1999-09-21 | Hoffmann-La Roche Inc. | Method of treating diseases of the CNS |
| JPH11171702A (ja) | 1997-09-24 | 1999-06-29 | Takeda Chem Ind Ltd | 害虫防除方法 |
| US6395876B1 (en) | 1997-12-05 | 2002-05-28 | Medical College Of Georgia Research Institute, Inc. | High-affinity tryptophan transporter |
| HUP0102415A3 (en) | 1997-12-10 | 2002-03-28 | Dainippon Ink & Chemicals | Oxime derivatives, intermediates, preparation thereof and agricultural chemicals containing the same |
| EP1084121B1 (en) | 1998-06-02 | 2002-07-31 | Takeda Chemical Industries, Ltd. | Oxadiazoline derivatives and their use as insecticides |
| FR2784678B1 (fr) | 1998-09-23 | 2002-11-29 | Sod Conseils Rech Applic | Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| KR100396738B1 (ko) | 1999-03-03 | 2003-09-03 | 삼진제약주식회사 | 피페라진 유도체 및 그 제조방법 |
| CA2370267A1 (en) | 1999-04-09 | 2000-10-19 | Basf Aktiengesellschaft | Prodrugs of thrombin inhibitors |
| EP1188747B1 (en) | 1999-05-24 | 2005-09-07 | Mitsubishi Pharma Corporation | Phenoxypropylamine compounds |
| JP2001158785A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 農薬組成物 |
| JP2001158786A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 哺乳動物の外部寄生虫防除剤 |
| WO2001051456A2 (en) | 2000-01-13 | 2001-07-19 | Tularik Inc. | Antibacterial agents |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| EP1444225B1 (en) * | 2001-06-18 | 2012-10-10 | Merck Serono SA | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists. |
| GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
| EP2177601A1 (en) | 2002-04-12 | 2010-04-21 | Medical College of Georgia Research Institute, Inc | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| RU2359967C2 (ru) | 2002-05-28 | 2009-06-27 | Джонсон энд Джонсон Фамэсьютикэл Рисеч энд Дивелопмент, эЛ.эЛ.Си | Производные тиофена и фармацевтическая композиция (варианты) |
| US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| CA2520172C (en) | 2003-03-27 | 2012-10-02 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor |
| US7598287B2 (en) * | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| CA2536253A1 (en) | 2003-08-20 | 2005-03-03 | Vertex Pharmaceuticals Incorporated | Aminofurazan compounds useful as protein kinase inhibitors |
| DE10348022A1 (de) * | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| TW200619212A (en) * | 2004-09-08 | 2006-06-16 | Mitsubishi Pharma Corp | Morpholine derivatives |
| EP1838706A1 (en) | 2004-12-24 | 2007-10-03 | Prosidion Limited | G-protein coupled receptor agonists |
| US7429667B2 (en) * | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| PL2559690T3 (pl) * | 2005-05-10 | 2016-09-30 | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania | |
| WO2006133417A1 (en) | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
| DE102005060466A1 (de) * | 2005-12-17 | 2007-06-28 | Bayer Cropscience Ag | Carboxamide |
| TWI382974B (zh) * | 2005-12-20 | 2013-01-21 | 英塞特公司 | 作為吲哚胺２，３-二氧化酶調節劑之ｎ-羥基甲脒基雜環化物 |
| US20070203140A1 (en) * | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| JP4297449B2 (ja) | 2006-05-12 | 2009-07-15 | 株式会社サクラクレパス | 墨汁 |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| JP5319532B2 (ja) | 2006-09-19 | 2013-10-16 | インサイト・コーポレイション | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロサイクル |
| US20080119491A1 (en) * | 2006-09-19 | 2008-05-22 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008036652A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| WO2008058178A1 (en) | 2006-11-08 | 2008-05-15 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008073825A1 (en) | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | Lxr and fxr modulators |
| TW200845991A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| ES2524266T3 (es) * | 2008-07-08 | 2014-12-04 | Incyte Corporation | 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa |
-
2007
- 2007-09-18 JP JP2009529341A patent/JP5319532B2/ja not_active Expired - Fee Related
- 2007-09-18 WO PCT/US2007/078745 patent/WO2008036642A2/en not_active Ceased
- 2007-09-18 EP EP07814905.1A patent/EP2064207B1/en active Active
- 2007-09-18 US US11/856,967 patent/US20080125470A1/en not_active Abandoned
- 2007-09-18 CA CA2663057A patent/CA2663057C/en active Active
- 2007-09-18 ES ES07814905.1T patent/ES2444574T3/es active Active
-
2011
- 2011-03-23 US US13/070,069 patent/US8377976B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP2064207B1 (en) | 2013-11-06 |
| JP5319532B2 (ja) | 2013-10-16 |
| ES2444574T3 (es) | 2014-02-25 |
| US20080125470A1 (en) | 2008-05-29 |
| WO2008036642A2 (en) | 2008-03-27 |
| JP2010504346A (ja) | 2010-02-12 |
| EP2064207A2 (en) | 2009-06-03 |
| WO2008036642A3 (en) | 2008-08-07 |
| CA2663057A1 (en) | 2008-03-27 |
| US8377976B2 (en) | 2013-02-19 |
| US20110172279A1 (en) | 2011-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2662773C (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
| US8377976B2 (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
| AU2019200404B2 (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | |
| AU2006244068B2 (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same | |
| US20080119491A1 (en) | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
| US20080146624A1 (en) | Amidines as modulators of indoleamine 2,3-dioxygenase | |
| US20080182882A1 (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
| JP5294874B2 (ja) | インドールアミン２，３−ジオキシゲナーゼのモジュレーターとしてのｎ−ヒドロキシアミジノヘテロ環 | |
| US20070203140A1 (en) | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | |
| AU2018267589A1 (en) | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | |
| HK40042435A (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | |
| HK1227857A1 (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | |
| HK1227857B (en) | Process for the synthesis of an indoleamine 2,3-dioxygenase inhibitor | |
| HK1182381B (en) | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD Year of fee payment: 17 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240905 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240905 |